topics / Novo Nordisk
Tagged Novo Nordisk.
- Preliminary human Amycretin An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere.
- Preliminary human Cagrilintide: A Long-Acting Amylin Analog with Strong Combination Data and Thin Standalone Evidence Cagrilintide is an investigational once-weekly amylin analog from Novo Nordisk. The robust human data are for the CagriSema combination, not the drug alone.
- Strong human CagriSema An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide.